메뉴 건너뛰기




Volumn 81, Issue 1, 2008, Pages 75-76

A case of coexistence between JAK2V617F and BCR/ABL

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2;

EID: 45449092604     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01063.x     Document Type: Letter
Times cited : (20)

References (5)
  • 1
    • 37749046766 scopus 로고    scopus 로고
    • Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era
    • Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006 240 5.
    • (2006) Hematology Am Soc Hematol Educ Program , pp. 240-5
    • Tefferi, A.1
  • 3
    • 34447639429 scopus 로고    scopus 로고
    • Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis
    • Bornhauser M, Mohr B, Oelschlaegel U, Bornhauser P, Jacki S, Ehninger G, Thiede C. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007 21 : 1824 6.
    • (2007) Leukemia , vol.21 , pp. 1824-6
    • Bornhauser, M.1    Mohr, B.2    Oelschlaegel, U.3    Bornhauser, P.4    Jacki, S.5    Ehninger, G.6    Thiede, C.7
  • 4
    • 34247397427 scopus 로고    scopus 로고
    • Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation
    • Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, Kreipe HH. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007 109 : 4106 7.
    • (2007) Blood , vol.109 , pp. 4106-7
    • Hussein, K.1    Bock, O.2    Seegers, A.3    Flasshove, M.4    Henneke, F.5    Buesche, G.6    Kreipe, H.H.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.